

# American Leading Life Sciences Research Services Platform



**MERGERSCORP**

## American Leading Life Sciences Research Services Platform

A leading independent multi-omics service providers in the Americas.

The Company provides a comprehensive portfolio of next-generation sequencing (NGS), proteomics, metabolomics, epigenomics, and bioinformatics solutions to research institutions, hospitals, biotechnology companies, and pharmaceutical clients across North and South America.

Following the transaction, the Company will become a fully independent platform with significant opportunities for organic expansion, operational optimization, and strategic acquisitions.

### Investment Highlights

#### 1. Attractive Exposure to High-Growth Precision Medicine

The global sequencing services market continues to expand at approximately 20% CAGR, driven by precision medicine, drug discovery, oncology, genomics research, and increasing outsourcing by pharmaceutical companies.

The Company is exceptionally well positioned to capitalize on these structural growth trends.

#### 2. Established Market Leader Across the Americas

- Local laboratory operations
- Sales teams throughout the Americas
- Comprehensive service offering
- Strong reputation among research institutions
- Scalable operating platform

#### 3. Blue-Chip Customer Base

Trusted by leading universities, hospitals and global pharmaceutical companies, including:

- Stanford University
- University of California
- AbbVie
- Pfizer
- AstraZeneca
- Novo Nordisk
- Amgen
- Bristol Myers Squibb
- Gilead
- Sanofi

#### 4. Proprietary Laboratory Automation

#### GROSS REVENUE

\$57,000,000

#### EBITDA

\$3,700,000

#### BUSINESS TYPE

#### COUNTRY

United States

#### BUSINESS ID

L#20261103

The Company has invested significantly in proprietary laboratory automation, delivering:

- 60% reduction in production cycle
- 400 samples/day per production line
- 25% higher production capacity
- 100% productivity improvement
- Industry-leading sequencing quality

These capabilities create meaningful barriers to entry while supporting strong operating leverage.

#### 5. Highly Diversified Service Portfolio

The platform provides end-to-end solutions across:

- Next Generation Sequencing
- Single Cell Sequencing
- Epigenomics
- Metagenomics
- Proteomics
- Metabolomics
- Bioinformatics
- Custom Research Services

#### 6. Experienced Scientific Management Team

The business is led by an experienced scientific leadership team with deep expertise in molecular biology, genomics, laboratory operations, and commercial development.

The existing management team is expected to provide operational continuity following the transaction.

#### 7. Significant Value Creation Potential

Following separation from its listed parent company, investors will benefit from:

- Independent strategic direction
- Operational optimization
- Margin enhancement initiatives
- Geographic expansion
- New laboratory development
- Potential bolt-on acquisitions
- Long-term IPO or strategic exit opportunities

#### Transaction Overview

##### Opportunity

Acquisition of a controlling interest in a leading U.S.-based multi-omics platform.

##### Seller

Publicly listed multinational corporation.

#### Transaction Structure

Flexible transaction structure, including share acquisition and/or primary capital injection.

#### Expected Closing



*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

## MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

**MERGERSCORP**

[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)